No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
ZVRA250117C12000
- 0.00
- 0.000.00%
15min DelayClose Jan 10 09:30 ET
0.00High0.00Low
0.00Open0.00Pre Close0 Volume0 Open Interest12.00Strike Price0.00Turnover0.00%IV47.97%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier6DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma8.11Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
No Data
News
Cantor Fitzgerald Initiates Zevra Therapeutics(ZVRA.US) With Buy Rating, Announces Target Price $25
Zevra Therapeutics (ZVRA) Receives a Buy From Cantor Fitzgerald
Analysts Expect Breakeven For Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Before Long
Top Picks for 2025 in Healthcare, Consumer, Tech, Industrials, Energy and More
Zevra Therapeutics to Be Added to Nasdaq Biotechnology Index (Nasdaq: NBI) Effective December 23, 2024
Zevra Therapeutics Restructures to Focus on Rare Diseases